Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29960515 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPTMEN1KCNA5 | |
| SCHEMBL224028 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPTMEN1KCNA5 | |
| SCHEMBL4098064 | 0.79 | ALDH1A1 (0.50) | ALDH1A1PTPN11KMT2AMAPTMEN1 | |
| SCHEMBL18993220 | 0.78 | ALDH1A1 (0.48) | ALDH1A1KMT2AMAPTMEN1EGFR | |
| SCHEMBL2884609 | 0.77 | TSHR (0.41) | ALDH1A1PTPN11CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL10191914 | 0.77 | ALDH1A1 (0.46) | ALDH1A1PTPN11CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL12129057 | 0.76 | ALDH1A1 (0.67) | ALDH1A1CYP1A2KMT2AMAPTMEN1 | |
| SCHEMBL10191916 | 0.75 | KCNA5 (0.44) | ALDH1A1PTPN11CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL10191902 | 0.74 | ALDH1A1 (0.59) | ALDH1A1PTPN11CYP1A2KMT2AMEN1 | |
| SCHEMBL22658427 | 0.74 | PTPN11 (0.57) | ALDH1A1PTPN11KMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | EIF2AK2, INMT, IDO1 | ALDH1A1 1556/4885PTPN11 4167/4885CYP1A1 2265/4885 |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | ALDH1A1 563/4885PTPN11 3278/4885CYP1A1 1193/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | ALDH1A1 591/4885PTPN11 4442/4885CYP1A1 3292/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | ALDH1A1 1497/4885PTPN11 3619/4885CYP1A1 3730/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | ALDH1A1 1497/4885PTPN11 3619/4885CYP1A1 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.